Lymphocyte‐monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low‐grade B‐cell lymphoma. (28th April 2020)

• Record Type: Journal Article
• Authors: Shimono, Joji; Izumiyama, Koh; Ito, Shinichi; Tsutsmi, Yutaka; Kondo, Takeshi; Kakinoki, Yasutaka; Teshima, Takanori
• Is Part Of: International journal of laboratory hematology. Volume 42:Number 4(2020:Aug.)
• Page Start: 431
• Page End: 438
• Publication Date: 2020-04-28
• Subjects: bendamustine -- lmr -- low‐grade B‐cell lymphoma -- malignant lymphoma; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; 616.15005
• DOI: 10.1111/ijlh.13216
• Languages: English
• ISSNs: 1751-5521

Abstract

Abstract: Introduction: Bendamustine has been reported to be effective against low‐grade B‐cell lymphoma. We examined the effect of bendamustine on the lymphocyte‐monocyte ratio (LMR) in low‐grade B‐cell lymphoma patients. Methods: We retrospectively reviewed 127 cases of first line or relapse/refractory low‐grade B‐cell lymphoma in three individual institutions (Asahikawa Municipal Hospital, Aiiku Hospital, and Hakodate Municipal Hospital). Only patients who had received at least three courses of bendamustine therapy were selected; the LMR was evaluated at starting the initial course of bendamustine therapy. Time to next treatment (TTNT) was used to ascertain the efficacy of bendamustine therapy. Results: Follicular lymphoma (FL), at 68.5% (87/127), is the most common histological subtype of low‐grade B‐cell lymphoma. The receiver operating characteristic (ROC) curve for the LMR showed a cutoff value of 2.0, and 33 cases (26.0%) had an LMR ≤2.0. Cases with LMR ≤2.0 had a significantly earlier progression than those with LMR > 2.0, based on the TTNT ( P = .0007). Additionally, LMR ≤2.0 indicates earlier progression in TTNT when comparing only FL and low‐grade B‐cell lymphoma cases without FL ( P = .007, 0.002). For multivariate analysis, the factors associated with an LMR ≤2.0 (HR, 2.741; 95% CI, 1.4330‐5.245; P = .002) were considered as early progression factors with regard to the TTNT. Conclusion: Lymphocyte‐monocyte ratio effectively predicts the efficacy of bendamustine therapy for low‐grade B‐cell lymphoma, particularly FL; its application may improve treatment strategies for this disease.